Trial Profile
A study of Cytomegalovirus-specific T-cell therapy for the treatment of cytomegalovirus infection
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 May 2016
Price :
$35
*
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 11 May 2016 New trial record
- 05 May 2016 According to an Atara Biotherapeutics media release, the company plans to discuss clinical trial design for Cytomegalovirus Cytotoxic T-Lymphocyte (CMV-CTLs) with FDA this year and intends initiate this trial in the year 2017.